Form 4: Akero Therapeutics COO Jonathan Young Sells Shares to Cover Tax Obligations

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 607 shares of common stock on March 12, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 12, 2025, Jonathan Young, the Chief Operating Officer of Akero Therapeutics, Inc., sold 607 shares of common stock at a price of $44.88 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units, in accordance with the company's 'sell-to-cover' policy.
• Following the transaction, Young directly owns 200,540 shares of Akero Therapeutics common stock.
• Young also has indirect ownership of 20,000 shares each through three irrevocable trusts (EA Irrevocable Trust, CM Irrevocable Trust, and JL Irrevocable Trust) for the benefit of his children, for which his spouse serves as trustee.
• Young disclaims beneficial ownership of the shares held in these trusts.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing relates to a routine stock sale for tax purposes and doesn't indicate any significant change in the insider's confidence in the company.

Positives

• The sale was part of a pre-existing 'sell-to-cover' policy, indicating a structured approach to managing tax obligations.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential sentiment.

Stakeholder Impact

• The sale of shares could have a minor impact on shareholders due to the slight dilution of equity.

Key Dates